(94 days)
No
The description focuses on the mechanical and control aspects of delivering radiation dose based on pre-determined treatment data, with no mention of AI/ML for tasks like treatment planning, image analysis, or adaptive therapy.
Yes
The device is used to apply a radionuclide source for radiation therapy, which is a treatment for a medical condition.
No
The device is described as applying a radionuclide source for radiation therapy to deliver a radiation dose distribution, which is a therapeutic function, not a diagnostic one.
No
The device description clearly lists multiple hardware components (Treatment Unit, Treatment Control Panel, etc.) in addition to software elements.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This testing is done outside the body (in vitro).
- MicroSelectron V3 Function: The description clearly states the MicroSelectron V3 is used to "apply, by remote control, a radionuclide source into the body... or to the surface of the body for radiation therapy." This is a therapeutic device that delivers radiation to the patient's body, not a device that analyzes samples from the body.
The device's purpose is to deliver radiation treatment, which is a therapeutic intervention, not a diagnostic test performed on a sample.
N/A
Intended Use / Indications for Use
The MicroSelectron V3 is intended to enable an operator to apply, by remote control, a radionuclide source into the body (including Interstitial, Intracavitary, Intraluminal, Bronchial, Endovascular and Intra-operative) or to the surface of the body for radiation therapy.
Product codes
JAQ
Device Description
The MicroSelectron V3 delivers a radiation dose distribution conforming to treatment data, which is either, manually entered at the workstation or imported from a treatment planning system. For a treatment, a source and applicator are minimally required. Treatment can be administered via up to 30 applicators connected to 30 channels in the treatment unit. The dose distributions are achieved by sequentially letting the source dwell in required positions within the applicators. A channel has 48 possible dwell position has a number, whereby position 1 represents the farthest possible (distal) position from the treatment unit and 48 the closest (proximal) position. The step size, which is the minimum distance between the centres of consecutive dwell positions, can be set to 2.5 mm, or 10 mm. All channels that are used for a given treatment have the same step size. Treatment in a channel starts at the proximal programmed dwell position. When the dwell time in the proximal position has elapsed, treatment continues in the next programmed dwell position and so on until the last dwell position has been completed; whereupon, the procedure is repeated in the next programmed channel (if applicable). The required dose distribution can be delivered according to two principles:
- The "high dose rate brachytherapy" principle (HDR), i.e. only one treatment cycle as described above is given during a treatment session. The treatment is completed when the last programmed channel is completed.
- The "pulsed dose rate brachytherapy" principle (PDR), i.e. treatment cycles (pulses) are given at regular intervals (periods). A pulse includes treatment in a number of channels (determined by the user) depending on the type of application. After having delivered one pulse, the system enters a quiescent state, the duration of which is equal to the period time minus the pulse time. The period time is the elapsed time between two consecutive pulses. The second pulse starts at the end of the first period time. The whole sequence as described above for the first pulse will then be repeated. The treatment is completed when the last pulse has been delivered.
The MicroSelectron V3 consists of the following main components:
- Treatment Unit (TU): Contains a safe for the source, dual drive mechanisms with two stepper motors, position encoders for the source assembly and the check cable, a channel indexer, an electrical adjustment for the height of the treatment head, electronic control circuit boards, battery pack and the power supply.
- Treatment Control Panel (TCP): Transfers treatment data from the treatment control station to the treatment unit. Monitors treatment by exchanging status messages.
- Treatment Control Station (TCS): A computer with a monitor and a keyboard for user programmable functions, data entry, and detailed operational information. Performs self-test of components related to safe operation before treatment. Allows definition of multiple user types with different authorization levels. Stores patient, treatment, and applicator data in a database.
- Remote Control Unit (RCU) (optional for HDR): Mounted outside the treatment room, allows starting, interrupting, and resuming treatment. Provides information about treatment and system status.
- Nurse Station Display (Optional) (NSD): Gives staff members the possibility to remotely monitor the treatment and system status for up to four treatment units.
The radiotherapy treatment planning software is not part of this 510(k) submission. Applicators and Transfer Tubes as available for microSelectron-HDR/PDR (K953946 & K041933) are also applicable for the microSelectron V3 System.
The modifications to the previously cleared device K041933 are:
- Addition of HDR functionality, part of previously cleared device K902533.
- Increase of the number of channels of the indexer from 18 to 30.
- Addition of DICOM import and export functionality.
- Increase of maximum source strength for treatment of patients from 40.000 uGy.m3h (10Ci) to 48.000 µGy.m2/h (12Ci).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Body (including Interstitial, Intracavitary, Intraluminal, Bronchial, Endovascular and Intra-operative) or to the surface of the body.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Operator, nurse, physician; Treatment room, outside the treatment room (Remote Control Unit).
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5700 Remote controlled radionuclide applicator system.
(a)
Identification. A remote controlled radionuclide applicator system is an electromechanical or pneumatic device intended to enable an operator to apply, by remote control, a radionuclide source into the body or to the surface of the body for radiation therapy. This generic type of device may include patient and equipment supports, component parts, treatment planning computer programs, and accessories.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the word "Nucletron" in bold, black font, next to a square logo. The logo contains a black circle with two white circles on either side. The logo is enclosed in a black square.
NUCLETRON B.V.
Waardgelder 1 3905 TH Veenendaal 3900 AX Veenendaal P.O.Box 930 The Netherlands Phone +31 318 557133 Fax +31 318 550485
Department of Health and Human Services Centre of Device and Radiological Health Office of Device Evaluation Special 510(k) section
AUG 1 7 2006
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION as required by section 807.92(c)
Submitter of 510(k):
| Company name: | Nucletron Corporation |
|---|---|
| Registration number: | 1121753 |
| Address: | 8671 Robert Fulton Drive |
| Columbia, MD 21046 | |
| Phone: | 410-312-4100 |
| Fax: | 410-312-4197 |
| Correspondent: | Lisa Dimmick |
| Director Assurance & Regulatory Affairs |
Modified Device Name:
| Trade/Proprietary Name: | MicroSelectron V3 |
|---|---|
| Common/Usual Name: | Afterloader |
| Classification Name: | Remote controlled radionuclide applicator system |
| Classification: | 21Cfr892.5700 Class II |
| Product Code | JAQ |
Legally Marketed Device(s)
Our device is substantially equivalent to the legally marketed predicate device cited in the table below:
| 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
turer | --------------------------------------------------------------------------------------------------------
1000 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 -
Production |
|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Nucletron | Micro | KDA1024
| 1 |
|---|
Description:
The MicroSelectron V3 delivers a radiation dose distribution conforming to treatment data, which is either, manually entered at the workstation or imported from a treatment planning system.
For a treatment, a source and applicator are minimally required. Treatment can be administered via up to 30 applicators connected to 30 channels in the treatment unit. The dose distributions are achieved by sequentially letting the source dwell in required positions within the applicators,
1
A channel has 48 possible dwell position has a number, whereby position 1 represents the farthest possible (distal) position from the treatment unit and 48 the closest (proximal) position. The step size, which is the minimum distance between the centres of consecutive dwell positions, can be set to 2.5 mm, or 10 mm. All channels that are used for a given treatment have the same step size. Treatment in a channel starts at the proximal programmed dwell position. When the dwell time in the proximal position has elapsed, treatment continues in the next programmed dwell position and so on until the last dwell position has been completed; whereupon, the procedure is repeated in the next programmed channel (if applicable).
The required dose distribution can be delivered according to two principles:
- The "high dose rate brachytherapy"principle (HDR), i.e. only one treatment cycle as . described above is given during a treatment session. The treatment is completed when the last programmed channel is completed.
- . The "pulsed dose rate brachytherapy" principle (PDR), i.e. treatment cycles (pulses) are given at regular intervals (periods). A pulse includes treatment in a number of channels (determined by the user) depending on the type of application. After having delivered one pulse, the system enters a quiescent state, the duration of which is equal to the period time minus the pulse time. The period time is the elapsed time between two consecutive pulses. The second pulse starts at the end of the first period time. The whole sequence as described above for the first pulse will then be repeated. The treatment is completed when the last pulse has been delivered.
The MicroSelectron V3 consists of the following main components:
. Treatment Unit (TU)
The Treatment Unit contains:
- Safe for the source
- . Dual drive mechanisms with two stepper motors
- Position encoders for the source assembly and the check cable, respectively .
- . Channel indexer
- . An electrical adjustment for the height of the treatment head
- Electronic control circuit boards .
- Battery pack and the power supply .
. Treatment Control Panel (TCP)
The Treatment Control Panel (TCP) transfers treatment data from the treatment control station to the treatment unit. After the Start button is pressed at the TCP, the treatment unit will execute treatment according to this data. The TCP monitors a treatment by exchanging status messages with the treatment unit and treatment control station.
. Treatment Control Station (TCS)
The Treatment Control Station is a computer with a monitor and a keyboard for user programmable functions, data entry, and detailed operational information. Once the Treatment Control Station is activated, and before any radiation treatment can be initiated, the system performs a self-test of all components which relate to safe operation. This diagnostic program checks the system connections, memory status, backup battery status, indexer status, Control Panel indicators, internal clock and audible alarm. For data integrity and security the system allows the definition of multiple types of users with different levels of authorization. This authorization is linked to the users password for the Treatment Control Station.
Patient and treatment data as well as applicator data is stored in the database at the treatment control station. The database stores information of treatment sessions (fractions or pulses) given a course of treatment.
2
. Remote Control Unit (RCU) (optional for HDR)
The Remote Control Unit (RCU) is mounted outside the treatment room. After preparing a patient and programming the system, treatment can be started. Treatment can be interrupted and later resumed so that a nurse or physician can enter the treatment room and administer care to the patient. The unit also provides information about the treatment and system status.
. Nurse Station Display (Optional)
The Nurse Station Display (NSD) gives staff members the possibility to remotely monitor the treatment and system status. After selecting one of up to four treatment units, the information of the selected treatment unit is shown. The nurse station display works in the same way as the remote control unit for the treatment information, error information, settings, and audible alarm.
The radiotherapy treatment planning software is not part of this 510(k) submission. Applicators and Transfer Tubes as available for microSelectron-HDR/PDR (K953946 & K041933) are also applicable for the microSelectron V3 System.
The modifications to the previously cleared device K041933 are:
- Addition of HDR functionality, part of previously cleared device K902533 .
- . Increase of the number of channels of the indexer from 18 to 30.
- . Addition of DICOM import and export functionality
- . Increase of maximum source strength for treatment of patients from 40.000 uGy.m3h (10Ci) to 48.000 µGy.m2/h (12Ci)
Intended use:
The modified device has the same intended use as the legally marketed predicate device cited:
The MicroSelectron V3 is intended to enable an operator to apply, by remote control, a radionuclide source into the body (including Interstitial, Intracavitary, Intraluminal, Bronchial, Endovascular and Intra-operative) or to the surface of the body for radiation therapy.
Summary of technological considerations:
MicroSelectron V3 is substantially equivalent to the cleared predicate device, microSelectron PDR, 510(k)#: K041933.
Signature
3 APRIL 2006
Date
Name: Dick van Waes Title: Business Director Brachytherapy & Imaging Nucletron B.V. Veenendaal, The Netherlands
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "U.S. Department of Health & Human Services USA" around the perimeter. In the center of the circle is an abstract symbol that resembles an eagle or other bird.
Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850
AUG 1 7 2006
Ms. Lisa Dimmick Director Regulatory Affairs Nucletron Corporation 8671 Robert Fulton Drive COLUMBIA MD 21046
Re: K061354
Trade/Device Name: MicroSelectron V3 Regulation Number: 21 CFR 892.5700 Regulation Name: Remote controlled radionuclide applicator system Regulatory Class: II Product Code: JAQ Dated: July 17, 2006 Received: July 19, 2006
Dear Ms. Dimmick:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Image /page/3/Picture/10 description: The image is a circular logo with the letters "FDA" in the center. Above the letters, the numbers "1906-2006" are displayed. Below the letters, the word "Centennial" is written in a stylized font. Three stars are arranged below the word "Centennial". The logo appears to be a commemorative emblem for the FDA's centennial anniversary.
Promoting Public .
4
Page 2 -
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology) | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 894.xxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150
or at its Internet address http://www.fda.gov/cdrl/industry/support/index.html.
Sincerely yours,
Nancy C. Hogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use Statement
510(k) Number
Device Name
Indications for Use
MicroSelectron V3
The MicroSelectron V3 is intended to enable an operator to apply, by remove control, a radionvelide source into the body (including Interstitial, Intracavitary, Intraluminal, Bronchial, Endovascular and Intra-operative) or to the surface of the body for radiation therapy.
PLEASE DO NOT VRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED
OR
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
Over-The-Counter Use
Nancy Brodon
(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number _